Viridian therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the compensation committee of the company's board of directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (t.
NDAQ Ratings Summary
NDAQ Quant Ranking